Amplification of tumor inducing putative cancer stem cells (CSCs) by vitamin A/retinol from mammary tumors

•Vitamin A supports self renewal of putative CSCs from mammary tumors.•These cells exhibit impaired retinol metabolism into retinoic acid.•CSCs from mammary tumors differentiate into mammary specific cell lineages.•The cells express mammary stem cell specific CD29 and CD49f markers.•Putative CSCs fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochemical and biophysical research communications 2013-07, Vol.436 (4), p.625-631
Hauptverfasser: Sharma, Rohit B., Wang, Qingde, Khillan, Jaspal S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Vitamin A supports self renewal of putative CSCs from mammary tumors.•These cells exhibit impaired retinol metabolism into retinoic acid.•CSCs from mammary tumors differentiate into mammary specific cell lineages.•The cells express mammary stem cell specific CD29 and CD49f markers.•Putative CSCs form highly metastatic tumors in NOD SCID mouse. Solid tumors contain a rare population of cancer stem cells (CSCs) that are responsible for relapse and metastasis. The existence of CSC however, remains highly controversial issue. Here we present the evidence for putative CSCs from mammary tumors amplified by vitamin A/retinol signaling. The cells exhibit mammary stem cell specific CD29hi/CD49fhi/CD24hi markers, resistance to radiation and chemo therapeutic agents and form highly metastatic tumors in NOD/SCID mice. The cells exhibit indefinite self renewal as cell lines. Furthermore, the cells exhibit impaired retinol metabolism and do not express enzymes that metabolize retinol into retinoic acid. Vitamin A/retinol also amplified putative CSCs from breast cancer cell lines that form highly aggressive tumors in NOD SCID mice. The studies suggest that high purity putative CSCs can be isolated from solid tumors to establish patient specific cell lines for personalized therapeutics for pre-clinical translational applications. Characterization of CSCs will allow understanding of basic cellular and molecular pathways that are deregulated, mechanisms of tumor metastasis and evasion of therapies that has direct clinical relevance.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2013.05.141